HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Aggressive Claims, FDA Warnings Make Beauty A Bull’s Eye For Litigation

This article was originally published in The Rose Sheet

Executive Summary

Class-action suits against beauty firms on the rise as industry pushes the envelope with claims and FDA warning letters draw attention from class-action law firms, legal experts note. Hogan Lovells attorney Mark Goodman says: “I don’t see this [trend] going away anytime soon.”


Related Content

FDA Warns Reviva Labs For Collagen-Building, Anti-Inflammatory Claims
L’Oreal Settles With FTC Over Gene-Related Anti-Aging Skin-Care Claims
Regulatory Action Is Lesser Of Firms’ Worries Amid Class-Action Blitz
FTC Proposes Settlement On Firms’ Genetic Skin-Care, Supplement Claims
Top Stories Of 2013: Retailers, Firms Self-Regulate As Consumer Power Grows
Aveeno Faces Class Actions Over “Naturals” Claims
J&J Settles Class Action For “Misleading” Neutrogena Naturals Claims
Clinique’s Scientific Language Misleads Consumers – Suit
In Brief
Coty/Rimmel Targeted With Suit Over Lash Accelerator Claims

Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts